ロード中...
The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations
The nonvitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban are used for the reduction of the risk of stroke or systemic embolism (SEE) in patients with nonvalvular atrial fibrillation (NVAF). The purpose of this review is to highlight the safety and effic...
保存先:
| 出版年: | J Atr Fibrillation |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Cardiofront, Inc
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5673394/ https://ncbi.nlm.nih.gov/pubmed/29250278 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4022/jafib.1547 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|